Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
September 30, 2026 -36.46M
June 30, 2026 -88.83M
March 31, 2026 -222.74M
December 31, 2025 -247.60M
September 30, 2025 -219.76M
June 30, 2025 -205.57M
March 31, 2025 -262.09M
December 31, 2024 -195.98M
September 30, 2024 -180.92M
June 30, 2024 -122.95M
March 31, 2024 -184.04M
December 31, 2023 -129.60M
September 30, 2023 -136.33M
June 30, 2023 -122.79M
March 31, 2023 -147.52M
December 31, 2022 -103.15M
September 30, 2022 -89.83M
June 30, 2022 -102.30M
March 31, 2022 -105.16M
December 31, 2021 -84.13M
September 30, 2021 -75.44M
June 30, 2021 -75.44M
March 31, 2021 -128.28M
December 31, 2020 -66.79M
September 30, 2020 -58.67M
Date Value
June 30, 2020 -35.95M
March 31, 2020 -57.94M
December 31, 2019 -44.40M
September 30, 2019 -52.37M
June 30, 2019 -80.03M
March 31, 2019 -73.85M
December 31, 2018 -69.54M
September 30, 2018 -65.49M
June 30, 2018 -54.91M
March 31, 2018 -68.04M
December 31, 2017 -48.22M
September 30, 2017 -38.24M
June 30, 2017 -36.25M
March 31, 2017 -36.91M
December 31, 2016 -57.96M
September 30, 2016 -30.98M
June 30, 2016 -28.24M
March 31, 2016 -29.53M
December 31, 2015 -27.55M
September 30, 2015 -24.03M
June 30, 2015 -24.24M
March 31, 2015 -24.88M
December 31, 2014 -12.93M
September 30, 2014 -20.90M
June 30, 2014 -17.93M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 340.98M
Gilead Sciences, Inc. 5.035B
Incyte Corp. -675.32M
Madrigal Pharmaceuticals, Inc. 120.56M
Vertex Pharmaceuticals, Inc. 643.10M